Literature DB >> 20600453

An evaluation of chemical photoreactivity and the relationship to phototoxicity.

Mark H Kleinman1, Mark D Smith, Edit Kurali, Sarah Kleinpeter, Kaina Jiang, Yongxia Zhang, Sonya A Kennedy-Gabb, Anthony M Lynch, Chris D Geddes.   

Abstract

The existing regulatory guidance for photosafety testing of new drug products states that studies are warranted for those chemicals that both absorb light in the range of 290-700 nm, and that are either applied locally/topically, or "reach" (EMEA)/"significantly partition" (FDA) to the skin or eyes. The initial in vitro study recommended for the assessment of phototoxic potential is the 3T3 Neutral Red Uptake (NRU) Assay. The current study was undertaken to establish superior triggers for the initiation of biological photosafety testing. In this study, photophysical and photochemical parameters for 40 drug or drug-like molecules were studied. Principal Component Analysis (PCA), Partial Least Squares-Discriminant Analysis (PLS-DA), and a fivefold cross-validation PLS algorithm were used to evaluate the relationship between subsets of photophysical and photochemical parameters with the 3T3 NRU PIF/MPE (Photo Irritation Factor/Mean Photo Effect) results. The parameters most indicative of a 3T3 NRU positive PIF or MPE score were the extent of degradation in solution, the quantum yield of formation of singlet oxygen and the relative formation of superoxide anion. The results demonstrate that while absorption of light is critical to the induction of a light-induced process, it is the resultant events that may be used to predict the 3T3 NRU assay result. It is therefore proposed that the trigger for photosafety testing be revised to include a molecular basis for photoreactivity. From this limited investigation, estimated thresholds leading to 3T3 NRU positive results due to photodegradation, formation of singlet oxygen quantum yield or a relative superoxide anion formation value are proposed.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600453     DOI: 10.1016/j.yrtph.2010.06.013

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  6 in total

1.  Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms.

Authors:  Karen M Alsante; Kim Huynh-Ba; Steven W Baertschi; Robert A Reed; Margaret S Landis; Mark H Kleinman; Christopher Foti; Venkatramana M Rao; Paul Meers; Andreas Abend; Daniel W Reynolds; Biren K Joshi
Journal:  AAPS PharmSciTech       Date:  2013-11-27       Impact factor: 3.246

Review 2.  Phototoxicity of traditional chinese medicine (TCM).

Authors:  Xiaoqi Li; Rui An; Kun Liang; Xinhong Wang; Lisha You
Journal:  Toxicol Res (Camb)       Date:  2018-08-27       Impact factor: 3.524

3.  Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones.

Authors:  Yoshiki Seto; Ryo Inoue; Masanori Ochi; Graham Gandy; Shizuo Yamada; Satomi Onoue
Journal:  AAPS J       Date:  2011-07-08       Impact factor: 4.009

4.  Phototoxicity Evaluation of Pharmaceutical Substances with a Reactive Oxygen Species Assay Using Ultraviolet A.

Authors:  Yong Sun Lee; Jung-Sun Yi; Hye Rim Lim; Tae Sung Kim; Il Young Ahn; Kyungyuk Ko; JooHwan Kim; Hye-Kyung Park; Soo Jung Sohn; Jong Kwon Lee
Journal:  Toxicol Res       Date:  2017-01-15

5.  Exploration of alternative test methods to evaluate phototoxicity of ophthalmic agents by using Statens Seruminstitut Rabbit Cornea cell lines and 3D human reconstituted cornea models.

Authors:  Soyoung Kim; Ki Hwan Choi; Jaesuk Yun
Journal:  PLoS One       Date:  2018-05-21       Impact factor: 3.240

Review 6.  Photosensitivity Reactions Induced by Photochemical Degradation of Drugs.

Authors:  Hajnal Klelemen; Gabriel Hancu; Edina Kacsó; Lajos-Attila Papp
Journal:  Adv Pharm Bull       Date:  2021-05-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.